Transactions
- Asset sale of
- Qutenza & NP-1998 to
- $13,000,000
- Partnering of
- Phase 2 RP101 with
- €13,000,000
- Partnering of
- Phase 2 AP301/solnatide with
- €6,000,000
- Raised first financing Series A, Series B & Common Stock
- $3,000,000
- Partnering of
- Phase 3 APN-311 with
- Not Disclosed
- Partnering of
- Phase 3 APN-311 with
- Not Disclosed
- Partnering of
- Phase 3 APN-311 with
- Not Disclosed
- Partnering of
- DGAT-1 Inhibitors with
- Not Disclosed
- Partnering of
- Phase 2 Axomadol with
- Not Disclosed
- Sale of
- to
- Not Disclosed
- Sale of
- to
- Not Disclosed
- Partnering of
- Phase 3 safinamide with
- Not Disclosed
- In-Licensing by
- of 2 Clinical Assets from
- Not Disclosed
- Sale of
- 8 Pre-Clinical & Phase 1 Assets to
- Not Disclosed
- Partnering of
- Phase 1/2 Estybon with
- Not Disclosed